Development
ADMA Biologics, Inc.
ADMA
$18.54
-$0.42-2.22%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -28.24M | -22.83M | -40.29M | -47.68M | -65.90M |
| Total Depreciation and Amortization | 8.32M | 8.16M | 7.93M | 7.56M | 7.11M |
| Total Amortization of Deferred Charges | 2.60M | 2.39M | 2.65M | 2.31M | 2.40M |
| Total Other Non-Cash Items | 36.24M | 9.83M | 9.35M | 8.96M | 15.17M |
| Change in Net Operating Assets | -10.12M | -13.73M | -21.08M | -19.35M | -18.29M |
| Cash from Operations | 8.80M | -16.18M | -41.45M | -48.22M | -59.51M |
| Capital Expenditure | -4.77M | -7.32M | -9.95M | -13.01M | -13.91M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -210.00K | -- | -- | -- | -- |
| Cash from Investing | -4.98M | -7.32M | -9.95M | -13.01M | -13.91M |
| Total Debt Issued | 135.00M | 0.00 | 0.00 | 0.00 | 151.75M |
| Total Debt Repaid | -158.60M | -24.80K | -34.00K | -36.60K | -100.04M |
| Issuance of Common Stock | 1.10M | 65.92M | 65.29M | 64.82M | 64.82M |
| Repurchase of Common Stock | -1.42M | -3.14M | -3.36M | -3.45M | -2.90M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.08M | -100.00 | -404.70K | -404.70K | -4.78M |
| Cash from Financing | -38.99M | 62.75M | 61.49M | 60.93M | 108.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.17M | 39.25M | 10.10M | -300.20K | 35.43M |